XELJANZ (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis Pharmaceutical Investing
PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement Biotech Investing
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis Genetics Investing
Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU Pharmaceutical Investing
